Cardiovascular Interventions, Electrophysiology and Peripheral Arterial Disease

Johnson and Johnson Completes Acquisition of Shockwave Medical

DAIC

MAY 31, 2024

This transaction further extends Johnson & Johnson MedTech’s leadership in cardiovascular intervention. Shockwave is ultimately expected to become Johnson & Johnson MedTech’s thirteenth priority platform, as defined by annual sales of at least $1 billion.

Peripheral Arterial Disease

Peripheral Arterial Disease Innovation Coronary Artery Disease Cardiovascular Interventions

Johnson and Johnson to Acquire Shockwave Medical

DAIC

APRIL 5, 2024

The acquisition of Shockwave further extends Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerates its shift into higher-growth markets. Cardiovascular intervention is one of the fastest-growing global medtech markets, with significant unmet patient need.

Cardiovascular Interventions

Cardiovascular Interventions Technology Innovation Angina

Cardiovascular Update

Johnson and Johnson Completes Acquisition of Shockwave Medical

Johnson and Johnson to Acquire Shockwave Medical

Webinars

Stay Connected